Wednesday, November 18, 2026

Biotech's Cash Cushion Meets a Risk-Off Market: What Incyte's Filings and a Wave of 2027 Milestones Show

Tech sold off $1 trillion in a day while small biotechs promise data in 2027. Incyte's SEC-verified cash fell from $3.2B to $1.7B and rebuilt to $3.3B. That shows how much a funded balance sheet matters when capital tightens. Source reliability is flagged where we measured it.

Via News Editorial Team

November 17, 2026

This article was generated by AI. Built from the source documents listed below. How we work

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Biotech's Cash Cushion Meets a Risk-Off Market: What Incyte's Filings and a Wave of 2027 Milestones Show
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

The money question behind the pipelines

On October 30, 2026, a $1 trillion tech selloff deepened fears of an AI bubble, and the Nasdaq 100 had its worst day since June.1 The next day, OpenAI cut its funding target by $10 billion.2 On November 1, Binance users withdrew $3.6 billion when the exchange reopened after a hack.3 None of these events involves a drug. But they set the price of money for every company that has no product revenue yet, and that is most of the small biotechs now reporting results.

The question for an investor is simple. Who can keep funding trials until the data arrives? The dossier we hold has one company with a deep, SEC-checked financial record, Incyte, so we use it as the yardstick. For the small names it carries milestones and guidance but few audited numbers. We say so where that matters.

What a funded balance sheet looks like: Incyte

Incyte is a commercial-stage company, so it is not a like-for-like peer for a pre-revenue biotech. Its cash history is useful for a different reason: it shows how much a cash balance can move in a year.

Incyte held $3.21 billion in cash at the end of fiscal 2023.4 By the end of fiscal 2024 that was $1.69 billion.4 The quarterly record shows the path: $3.35 billion in Q1 2024, then $987 million in Q2 2024, then $1.30 billion in Q3 2024.4 Our dossier does not say what caused the drop, so we will not guess. The point is that a large biotech's cash fell by roughly half within a year and then recovered.

Fiscal 2025 closed at $3.10 billion.4 The 2026 quarters read $3.46 billion (Q1), $3.98 billion (Q2) and $3.28 billion (Q3).4 To picture the scale, Q3 2026 cash is roughly nine times Incyte's entire fiscal 2025 cost of revenue of $372 million.5 (That ratio is Via News arithmetic on two verified figures.) It is also close to the $3.6 billion that left Binance in a day.3

Cost of revenue, the direct cost of making what Incyte sells, has climbed steadily: $255 million in fiscal 2023, $312 million in fiscal 2024 and $372 million in fiscal 2025.5 Quarterly figures show the pace slowing. Q1 2026 was $104.5 million against $73.2 million a year earlier. Q2 2026 was $105.0 million against $78.8 million. Q3 2026 was $108.7 million against $99.0 million.5 By our arithmetic that is growth of about 43%, 33% and 10% year on year. Sales figures are not in our dossier, so we cannot say whether margins moved. A falling growth rate in cost alone is not good or bad news.

One caution on data quality. Capital spending is recorded as exactly $48.7 million for both fiscal 2024 and fiscal 2025.6 Identical figures in consecutive years can be coincidence or a data artefact. We present it as filed and would not build a conclusion on it. Fiscal 2023 earnings per share were $2.65.7

The dossier's entity record links Incyte to Jakafi, Opzelura, pemigatinib and a candidate called INCB186748, and shows a licence to Dermavon Holdings Limited. The topic also names partnerships with BMS and Synnovation, but our dossier holds no deal terms for them. We therefore cannot say how much those deals contribute to Incyte's cash.

The small caps: milestones, not yet audited runways

The smaller companies each give the market a date to hold them to. Our dossier does not contain their cash balances, so this section shows what they have promised, not whether they can pay for it.

Scribe Therapeutics reported Q3 2026 results on November 12. It lists on Nasdaq under SCTX and has raised capital to fund the initial development of STX-1150, STX-1200 and STX-1400. Its first-in-human trial of STX-1150, an epigenetic silencing therapy for LDL cholesterol, is still enrolling, with initial data expected in the first half of 2027. It also expanded its collaboration with Sanofi.8 Scribe argues that current LDL-C therapies suffer from poor persistence, with studies showing 50% to 70% of patients stop within a year.8 It says naturally occurring PCSK9 loss-of-function variants are linked to 28% lower mean LDL-C and up to 88% lower coronary heart disease risk, and that STX-1150 aims to mimic that protection.8 These are the company's own statements, not independent findings.

Vor Bio announced final two-year Phase 3 results for telitacicept in IgA nephropathy. The annualised kidney-function decline was -0.6 against -5.7 mL/min/1.73 m² for placebo, a 5.1 difference (p<0.001), with 89% and 81% reductions in the risk of confirmed 30% and 40% declines.9 This is the strongest clinical result in our material, and it is also company-reported.

Akari Therapeutics plans Phase 1 development of AKTX-101 in mid-2027.10 Its position, in the company's words, is that patients whose cancers stopped responding to antibody drug conjugates are an unmet need and an exclusive opportunity for its novel payload.10 Ernexa says it remains on schedule to file its IND for ERNA-101 in the third quarter of 2026, with a first-in-human Phase 1 trial in the fourth quarter.11 Prelude guided to an IND for PRT13722 by mid-2026 and a Phase 1 start in ER-positive breast cancer in the second half of 2026.12 Both of those dates are already behind us or close. Our dossier does not confirm whether they were met, and that is the first thing to check. OPKO reported that its candidate OPK8801001 showed about 20-fold greater growth hormone receptor antagonism than Pegvisomant in vitro, meaning in a lab dish, not in patients.13

The royalty anchor: BioArctic

Not every biotech in this story is pre-revenue. BioArctic receives a royalty on Leqembi, sold through its partner Eisai. Eisai reported Leqembi sales of JPY 29.3 billion for Q2 2026, which produced a royalty to BioArctic of SEK 179 million, up about 10% on Q2 2025.14 The headline understates the trend. Q2 2025 included a one-time Chinese stockpiling effect of around JPY 5.3 billion, and excluding it, BioArctic says, royalty revenues grew approximately 43%.14 The company's own wording is: "Excluding the stockpiling effect, royalty revenues in Q2 2026 grew approximately 43 percent compared to the same quarter last year."14 This is what a royalty stream does for a small company: it funds the lab while the market is shut to new equity.

AI-bio: real firsts, thin evidence

Radical Numerics says AI-designed viruses have treated its first patient, in an experimental treatment for drug-resistant E. coli.15 That is a first-patient milestone, not an efficacy result, and our dossier contains no trial data to weigh it. Treat it as a demonstration stage.

A separate warning on source quality. A longevity startup, Generation Lab, says its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."16 That is a marketing claim, quoted as such. The MIT Technology Review items that carried it score 6% on our measured reliability, with 6% of 16 checked claims holding up. That is a small sample, but it is a reason for caution, not a reason for confidence.

How reliable are the sources?

The company press releases above come through NewsEOD, where 54% of 6,692 checked claims held up. That is a coin flip, so numbers from press releases deserve independent confirmation against filings. The Motley Fool comparison of AbbVie and Eli Lilly, cited in the topic's reference to Lilly's weight-loss demand, scores 31% of 58 claims.17 Our dossier carries no Lilly figures we can verify, so we make no claim about Lilly's numbers. Only the Incyte figures here are checked against SEC filings.

What to watch

  • Whether Prelude and Ernexa filed their INDs on the dates they guided, since the dossier cannot confirm it.
  • Scribe's first STX-1150 data in the first half of 2027, and its next quarterly cash disclosure.
  • Akari's mid-2027 Phase 1 start.
  • Incyte's next quarter: cost of revenue growth slowed to about 10% year on year in Q3 2026, and cash fell from $3.98 billion to $3.28 billion over the quarter.
  • Further moves in the tech funding market, since OpenAI's cut and the selloff are the clearest signs that capital is tightening.

Our read, as Via News analysis and not verified data: the sector is splitting into companies that can fund themselves, through royalties or large balance sheets, and companies that depend on the next raise. The evidence for this is indirect, and company cash runways are the number to find before buying any small cap named here.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMotley Fool
    AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
  2. [2]News articleYahoo Finance· October 15, 2026
    Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
  3. [3]News articleMIT Technology Review
    A startup claims it’s found a drug to make your blood young
  4. [4]News articleYahoo Finance· July 27, 2026
    OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
  5. [5]News articleYahoo Finance· July 29, 2026
    Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
  6. [6]News articleYahoo Finance· November 12, 2026
    Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
  7. [7]News articleYahoo Finance· October 22, 2026
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
  8. [8]News articleMIT Technology Review
    The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid
  9. [9]News articleMIT Technology Review
    The Download: a secretive antiaging drug and joining virtual power plants
  10. [10]News articleMIT Technology Review
    The Download: computing’s next leap and permafrost’s climate threat
  11. [11]Press releaseGlobeNewswire· July 15, 2026
    Three Biotechs Deliver Catalysts to Watch
  12. [12]News articleNasdaq· July 29, 2026
    Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 12 source documents from 5 publications, dated 15 Jul 2026 to 12 Nov 2026
  2. Published 17 Nov 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.